RU2598606C3 - Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она - Google Patents
Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-онаInfo
- Publication number
- RU2598606C3 RU2598606C3 RU2013123036A RU2013123036A RU2598606C3 RU 2598606 C3 RU2598606 C3 RU 2598606C3 RU 2013123036 A RU2013123036 A RU 2013123036A RU 2013123036 A RU2013123036 A RU 2013123036A RU 2598606 C3 RU2598606 C3 RU 2598606C3
- Authority
- RU
- Russia
- Prior art keywords
- phthalazin
- triazol
- fluorophenyl
- dihydro
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Claims (7)
1. Тозилатная соль (8S,9R)-5-фтор-8-(4-фторфенил)-9-(1-метил-1Н-1,2,4-триазол-5-ил)-8,9-дигидро-2Н-пиридо[4,3,2-de]фталазин-3(7Н)-она, где соль находится в кристаллической форме, где соль характеризуется диаграммой рентгеновской порошковой дифрактометрии, включающей характерные пики при следующих значениях выраженного в градусах угла 2θ±0,2 2θ 7,4, 15,1, 18,1, 20,1, 20,4, 22,6 и 24,0.
2. Тозилатная соль (8S,9R)-5-фтор-8-(4-фторфенил)-9-(1-метил-1Н-1,2,4-триазол-5-ил)-8,9-дигидро-2Н-пиридо[4,3,2-de]фталазин-3(7Н)-она по п. 1, где соль находится по существу в чистой кристаллической форме.
3. Тозилатная соль (8S,9R)-5-фтор-8-(4-фторфенил)-9-(1-метил-1Н-1,2,4-триазол-5-ил)-8,9-дигидро-2Н-пиридо[4,3,2-de]фталазин-3(7Н)-она по п. 1 или 2, где кристаллическая форма имеет чистоту по меньшей мере примерно 99,5%.
4. Тозилатная соль по п. 1 или 2, где кристаллическая форма является по существу свободной от аморфной формы (8S,9R)-5-фтор-8-(4-фторфенил)-9-(1-метил-1Н-1,2,4-триазол-5-ил)-8,9-дигидро-2Н-пиридо[4,3,2-de]фталазин-3(7Н)-она или его соли или сольвата.
5. Фармацевтическая композиция для лечения рака, включающая тозилатную соль по любому из пп. 1-4 и фармацевтически приемлемый эксципиент.
6. Фармацевтическая композиция по п. 5, где композиция сформулирована для орального введения субъекту.
7. Применение кристаллической тозилатной соли (8S,9R)-5-фтор-8-(4-фторфенил)-9-(1-метил-1Н-1,2,4-триазол-5-ил)-8,9-дигидро-2Н-пиридо[4,3,2-de]фталазин-3(7Н)-она для лечения рака груди у субъекта.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40547610P | 2010-10-21 | 2010-10-21 | |
| US61/405,476 | 2010-10-21 | ||
| PCT/US2011/057039 WO2012054698A1 (en) | 2010-10-21 | 2011-10-20 | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2013123036A RU2013123036A (ru) | 2014-11-27 |
| RU2598606C2 RU2598606C2 (ru) | 2016-09-27 |
| RU2598606C3 true RU2598606C3 (ru) | 2021-12-20 |
Family
ID=44903424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013123036A RU2598606C3 (ru) | 2010-10-21 | 2011-10-20 | Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8735392B2 (ru) |
| EP (2) | EP2630146B1 (ru) |
| JP (5) | JP2013540158A (ru) |
| KR (4) | KR20140009181A (ru) |
| CN (1) | CN103282365B (ru) |
| AR (1) | AR083502A1 (ru) |
| AU (2) | AU2011317040B2 (ru) |
| BR (1) | BR112013009117A2 (ru) |
| CA (1) | CA2814581C (ru) |
| CY (1) | CY1123356T1 (ru) |
| DK (1) | DK2630146T3 (ru) |
| ES (1) | ES2816600T3 (ru) |
| HU (1) | HUE051535T2 (ru) |
| IL (2) | IL225789B (ru) |
| MX (1) | MX362563B (ru) |
| NZ (1) | NZ609490A (ru) |
| PL (1) | PL2630146T3 (ru) |
| PT (1) | PT2630146T (ru) |
| RU (1) | RU2598606C3 (ru) |
| SG (2) | SG189939A1 (ru) |
| SI (1) | SI2630146T1 (ru) |
| TW (2) | TWI557123B (ru) |
| WO (1) | WO2012054698A1 (ru) |
| ZA (1) | ZA201302810B (ru) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2625817T3 (es) | 2008-08-06 | 2017-07-20 | Medivation Technologies, Inc. | Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
| US20120121515A1 (en) | 2009-03-13 | 2012-05-17 | Lenny Dang | Methods and compositions for cell-proliferation-related disorders |
| ES2632954T3 (es) | 2009-06-29 | 2017-09-18 | Agios Pharmaceuticals, Inc. | Derivados de quinolina-8-sulfonamida que tienen una actividad anticancerosa |
| WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| JP5883397B2 (ja) | 2010-02-03 | 2016-03-15 | ビオマリン プハルマセウトイカル インコーポレイテッド | Ｐｔｅｎ欠損に関連した疾患の治療におけるポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤の使用 |
| KR101826652B1 (ko) * | 2010-02-08 | 2018-02-07 | 메디베이션 테크놀로지즈, 인크. | 디히드로피리도프탈라지논 유도체의 합성 방법 |
| TWI557123B (zh) | 2010-10-21 | 2016-11-11 | 梅迪維新技術公司 | 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－***－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽 |
| SG194697A1 (en) | 2011-05-03 | 2013-12-30 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| EP2742030B1 (de) * | 2011-08-11 | 2016-07-27 | Bayer Intellectual Property GmbH | 1,2,4-triazolyl-substituierte ketoenole zum einsatz im pflanzenschutz |
| WO2013028495A1 (en) * | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| EP2906212A4 (en) | 2012-10-15 | 2016-06-08 | Agios Pharmaceuticals Inc | THERAPEUTIC COMPOUNDS AND COMPOSITIONS |
| EP3019480B1 (en) | 2013-07-11 | 2020-05-06 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| CA2939082C (en) | 2014-02-13 | 2022-06-07 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| ME03580B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
| PL3116491T3 (pl) * | 2014-03-14 | 2022-02-07 | Les Laboratoires Servier | Kompozycje farmaceutyczne związków terapeutycznie aktywnych |
| KR20240010105A (ko) * | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| AU2015296289B2 (en) * | 2014-07-31 | 2020-02-27 | Medivation Technologies Llc | Coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
| TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
| US11234976B2 (en) | 2015-06-11 | 2022-02-01 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
| CR20180152A (es) | 2015-08-12 | 2018-08-09 | Incyte Corp | Sales de un inhibidor de lsd1 |
| CA3216701A1 (en) | 2015-10-15 | 2017-04-20 | Les Laboratoires Servier | Combination therapy for treating malignancies |
| US10653710B2 (en) | 2015-10-15 | 2020-05-19 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
| JP2018536700A (ja) * | 2015-10-26 | 2018-12-13 | メディヴェイション テクノロジーズ， エルエルシー | Ｐａｒｐ阻害剤を用いる小細胞肺がんの治療 |
| CA3236518A1 (en) | 2016-02-29 | 2017-09-08 | F. Hoffmann-La Roche Ag | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| RU2020113246A (ru) | 2017-10-13 | 2021-11-15 | Мерк Патент Гмбх | Комбинация ингибитора parp и антагониста, связывающегося с осью pd-1 |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| US11368702B2 (en) | 2018-06-04 | 2022-06-21 | Lg Electronics, Inc. | Method and device for processing video signal by using affine motion prediction |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| US10942500B2 (en) * | 2018-06-11 | 2021-03-09 | Purdue Research Foundation | System architecture and method of processing data therein |
| US10382772B1 (en) * | 2018-07-02 | 2019-08-13 | Tencent America LLC | Method and apparatus for video coding |
| WO2020014700A1 (en) | 2018-07-13 | 2020-01-16 | Magic Leap, Inc. | Systems and methods for display binocular deformation compensation |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| EP3876940A1 (en) | 2018-11-05 | 2021-09-15 | Pfizer Inc. | Combinations for treating cancer |
| JP2023517044A (ja) | 2020-03-09 | 2023-04-21 | ファイザー・インク | 融合タンパク質およびその使用 |
| AU2021379314A1 (en) | 2020-11-13 | 2023-06-15 | Pfizer Inc. | Talazoparib soft gelatin capsule dosage form |
| US20240052423A1 (en) | 2020-12-07 | 2024-02-15 | Pfizer Inc. | Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof |
| JP2024510666A (ja) | 2021-03-24 | 2024-03-08 | ファイザー・インク | Ｄｄｒ遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ |
| WO2023131894A1 (en) | 2022-01-08 | 2023-07-13 | Pfizer Inc. | Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| WO2023233295A1 (en) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
| WO2024074959A1 (en) | 2022-10-02 | 2024-04-11 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415504A (en) | 1981-09-21 | 1983-11-15 | Tanabe Seiyaku Co., Ltd. | p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine |
| JPS58225065A (ja) | 1982-06-21 | 1983-12-27 | Nippon Shinyaku Co Ltd | ２−キノロン誘導体 |
| US5328905A (en) | 1987-07-20 | 1994-07-12 | Duphar International Research B.V. | 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives |
| GB9505538D0 (en) | 1995-03-18 | 1995-05-03 | Ciba Geigy Ag | New compounds |
| ID19155A (id) | 1996-12-13 | 1998-06-18 | Tanabe Seiyaku Co | Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya |
| DE19727410A1 (de) | 1997-06-27 | 1999-01-07 | Hoechst Schering Agrevo Gmbh | 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| TW430656B (en) | 1997-12-03 | 2001-04-21 | Dainippon Ink & Chemicals | Quinolinone derivative, method for preparing the same, and anti-allergic agent |
| CA2332239A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| JP2001302669A (ja) | 2000-04-18 | 2001-10-31 | Meiji Seika Kaisha Ltd | 三環性フタラジノン誘導体 |
| JP2002284699A (ja) | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
| AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
| SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
| BR0307780A (pt) * | 2002-02-19 | 2004-12-28 | Ono Pharmaceutical Co | Compostos derivados de piridazina fundida e medicamentos contendo os compostos como o ingrediente ativo |
| EP1340819A1 (en) | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Microsatellite markers |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| AU2003277674A1 (en) | 2002-11-12 | 2004-06-03 | Mochida Pharmaceutical Co., Ltd. | Novel parp inhibitors |
| CA2517629C (en) * | 2003-03-12 | 2011-07-12 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US7268138B2 (en) | 2003-05-28 | 2007-09-11 | Mgi Gp, Inc. | Compounds, methods and pharmaceutical compositions for inhibiting PARP |
| US20070197549A1 (en) | 2004-02-18 | 2007-08-23 | Astrazeneca Ab | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists |
| GB0612971D0 (en) | 2006-06-30 | 2006-08-09 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| CN101675040A (zh) | 2007-05-03 | 2010-03-17 | 辉瑞有限公司 | 作为钠通道调节剂的2-吡啶甲酰胺衍生物 |
| WO2009024190A1 (en) | 2007-08-22 | 2009-02-26 | 4Sc Ag | Indolopyridines as inhibitors of the kinesin spindle protein (eg5 ) |
| CN101998959B (zh) | 2008-02-06 | 2013-08-28 | 生物马林药物股份有限公司 | 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂 |
| ES2625817T3 (es) | 2008-08-06 | 2017-07-20 | Medivation Technologies, Inc. | Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
| BRPI0914556A2 (pt) | 2008-08-12 | 2015-08-04 | Boehringer Ingelheim Int | Processo para a preparação de compostos de piperazina substituídos por cicloalquila |
| JP5883397B2 (ja) | 2010-02-03 | 2016-03-15 | ビオマリン プハルマセウトイカル インコーポレイテッド | Ｐｔｅｎ欠損に関連した疾患の治療におけるポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤の使用 |
| US20110190266A1 (en) | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
| KR101826652B1 (ko) | 2010-02-08 | 2018-02-07 | 메디베이션 테크놀로지즈, 인크. | 디히드로피리도프탈라지논 유도체의 합성 방법 |
| WO2011130661A1 (en) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
| WO2011140009A1 (en) | 2010-05-04 | 2011-11-10 | Biomarin Pharmaceutical Inc. | Methods of using semi-synthetic glycopeptides as antibacterial agents |
| TWI557123B (zh) | 2010-10-21 | 2016-11-11 | 梅迪維新技術公司 | 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－***－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽 |
| WO2012166151A1 (en) | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml) |
| WO2013028495A1 (en) | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
| US20130053365A1 (en) | 2011-08-30 | 2013-02-28 | Biomarin Pharmaceutical, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| US20160280691A1 (en) | 2013-11-07 | 2016-09-29 | Biomarin Pharmaceutical Inc. | Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes |
| AU2015296289B2 (en) | 2014-07-31 | 2020-02-27 | Medivation Technologies Llc | Coformer salts of (2S,3S)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
-
2011
- 2011-10-20 TW TW100138150A patent/TWI557123B/zh active
- 2011-10-20 NZ NZ609490A patent/NZ609490A/en unknown
- 2011-10-20 BR BR112013009117A patent/BR112013009117A2/pt not_active Application Discontinuation
- 2011-10-20 KR KR1020137012297A patent/KR20140009181A/ko active Application Filing
- 2011-10-20 EP EP11777005.7A patent/EP2630146B1/en active Active
- 2011-10-20 CA CA2814581A patent/CA2814581C/en active Active
- 2011-10-20 ES ES11777005T patent/ES2816600T3/es active Active
- 2011-10-20 RU RU2013123036A patent/RU2598606C3/ru active Protection Beyond IP Right Term
- 2011-10-20 US US13/277,607 patent/US8735392B2/en active Active
- 2011-10-20 PL PL11777005T patent/PL2630146T3/pl unknown
- 2011-10-20 KR KR1020217006784A patent/KR20210028747A/ko not_active Application Discontinuation
- 2011-10-20 CN CN201180062085.0A patent/CN103282365B/zh active Active
- 2011-10-20 PT PT117770057T patent/PT2630146T/pt unknown
- 2011-10-20 TW TW105123467A patent/TWI643858B/zh active
- 2011-10-20 KR KR1020197030773A patent/KR20190120458A/ko not_active Application Discontinuation
- 2011-10-20 JP JP2013535079A patent/JP2013540158A/ja active Pending
- 2011-10-20 EP EP20175014.8A patent/EP3757106A1/en not_active Withdrawn
- 2011-10-20 SG SG2013029731A patent/SG189939A1/en unknown
- 2011-10-20 SG SG10201710578TA patent/SG10201710578TA/en unknown
- 2011-10-20 AR ARP110103892A patent/AR083502A1/es not_active Application Discontinuation
- 2011-10-20 WO PCT/US2011/057039 patent/WO2012054698A1/en active Application Filing
- 2011-10-20 MX MX2013004195A patent/MX362563B/es active IP Right Grant
- 2011-10-20 HU HUE11777005A patent/HUE051535T2/hu unknown
- 2011-10-20 SI SI201131903T patent/SI2630146T1/sl unknown
- 2011-10-20 AU AU2011317040A patent/AU2011317040B2/en active Active
- 2011-10-20 DK DK11777005.7T patent/DK2630146T3/da active
- 2011-10-20 KR KR1020187016905A patent/KR20180069132A/ko active Application Filing
-
2013
- 2013-04-17 IL IL225789A patent/IL225789B/en active IP Right Grant
- 2013-04-18 ZA ZA2013/02810A patent/ZA201302810B/en unknown
-
2014
- 2014-04-14 US US14/252,668 patent/US20140228369A1/en not_active Abandoned
-
2016
- 2016-11-18 JP JP2016224670A patent/JP2017061526A/ja active Pending
-
2017
- 2017-03-07 AU AU2017201564A patent/AU2017201564B2/en active Active
- 2017-07-17 US US15/651,735 patent/US10189837B2/en active Active
-
2018
- 2018-10-11 JP JP2018192521A patent/JP2019034951A/ja not_active Withdrawn
-
2019
- 2019-12-17 IL IL271497A patent/IL271497A/en unknown
-
2020
- 2020-07-09 JP JP2020118281A patent/JP2020169209A/ja not_active Withdrawn
- 2020-09-22 CY CY20201100893T patent/CY1123356T1/el unknown
-
2022
- 2022-08-02 JP JP2022123448A patent/JP2022140637A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2598606C3 (ru) | Кристаллическая тозилатная соль (8s,9r)-5-фтор-8-(4-фторфенил)-9-(1-метил-1н-1,2,4-триазол-5-ил)-8-9-дигидро-2н-пиридо[4,3,2-de]фталазин-3(7н)-она | |
| RU2014105881A (ru) | Ансольваты солей норибогаина | |
| HRP20211511T1 (hr) | Čvrsti oblici i formulacije (s)-4-(8-amino-3-(1-(but-2-inoil)pirolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida | |
| HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
| JP2014518266A5 (ru) | ||
| JP2006249089A5 (ru) | ||
| JP2014524442A5 (ru) | ||
| RU2599785C3 (ru) | Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина | |
| NZ627826A (en) | Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide | |
| IL214086A (en) | Malt salt of n- {4 - {[7,6- bis (methyllaxy) quinoline-4-yl] oxy} phenyl) - n- (4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms for cancer treatment | |
| JP2015522589A5 (ru) | ||
| JP2015522037A5 (ru) | ||
| RU2019121700A (ru) | Твердые формы апалутамида | |
| MX2012012571A (es) | Dicarboxamidas de ciclopropilo y analogos que muestran actividades anti-cancerosas y anti-proliferativas. | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| MX2014013039A (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple. | |
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| FI3694863T3 (fi) | Lorlatinibin vapaan emäksen hydraatin kidemuoto | |
| ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| RU2012146517A (ru) | Соли ральтегравира и их кристаллические формы | |
| JP2015509075A5 (ru) | ||
| JP2013508289A5 (ru) | ||
| HRP20150356T1 (hr) | Kristalni oblici soli prasugrela | |
| JP2015507020A5 (ru) | ||
| WO2014164648A4 (en) | Solid state forms of a quinazoline derivative and its use as a braf inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20200928 |
|
| ND4A | Extension of patent duration |
Effective date: 20211220 |